Fred Hirsch, MD, PhD

Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.

Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.

Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.

Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.

Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options.

Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment.

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.